Artwork
iconShare
 
Manage episode 522185345 series 3665342
Content provided by Audioboom and Applied Clinical Trials. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audioboom and Applied Clinical Trials or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
In today’s ACT Brief, we examine how the CRA role is transforming alongside modern clinical trial technology, review the FDA’s approval of Imfinzi plus FLOT as the first immunotherapy regimen for resectable gastric and GEJ cancers, and look at Novo Nordisk’s fast-tracked submission of its higher-dose Wegovy injectable under the Commissioner’s Priority Review Program.
  continue reading

111 episodes